(0.07%) 5 249.75 points
(0.02%) 39 651 points
(0.13%) 18 279 points
(0.40%) $78.57
(1.73%) $2.29
(-1.10%) $2 348.90
(-0.72%) $28.30
(0.03%) $1 007.50
(-0.11%) $0.927
(0.10%) $10.84
(-0.07%) $0.798
(-1.05%) $91.70
@ $18.19
Issued: 14 Feb 2024 @ 12:07
Return: -49.48%
Previous signal: Feb 14 - 11:05
Previous signal:
Return: -1.41 %
Live Chart Being Loaded With Signals
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases...
Stats | |
---|---|
Today's Volume | 292 694 |
Average Volume | 609 401 |
Market Cap | 1.47B |
EPS | $0 ( 2024-03-13 ) |
Next earnings date | ( $-0.350 ) 2024-06-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.78 |
ATR14 | $0.0230 (0.25%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-08 | Arch Venture Partners Xii, Llc | Buy | 1 176 593 | Common Stock |
2023-12-08 | Arch Venture Partners Xii, Llc | Buy | 703 061 | Common Stock |
2023-12-08 | Arch Venture Partners X, Llc | Buy | 1 176 593 | Common Stock |
2023-12-08 | Arch Venture Partners X, Llc | Buy | 703 061 | Common Stock |
2023-12-08 | Burow Kristina | Buy | 1 176 593 | Common Stock |
INSIDER POWER |
---|
35.66 |
Last 85 transactions |
Buy: 48 806 253 | Sell: 23 661 663 |
Volume Correlation
Neumora Therapeutics, Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Neumora Therapeutics, Correlation - Currency/Commodity
Neumora Therapeutics, Financials
Annual | 2022 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-0.860 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-0.860 |
Financial Reports:
No articles found.
Neumora Therapeutics,
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators